These findings declared that simultaneous inhibition of EGFR and FGFR1 activity may be a novel and effective strategy to overcome FGFR1-related EGFR-TKIs resistant in NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.